Despite today’s dip (-4.85%), JNJ still beat revenue estimates in Q4 FY2024 and maintains strong fundamentals. Analyst consensus remains Buy with a target price of $168.27 (+6.63%) Market overreaction or smart entry point Let’s hear your thoughts… #JNJ #StockTalk #BuyTheDip #ValuePlay #Earnings
$Pfizer (PFE.US)$up time only up by 10 to 15 cents…… when plunging time, it easily go down by 50 or more. its big time to short this stock and laugh our way to the bank.
1
1
Report
Demon Town
:
they did start shorting a week ago with huge volume, if you thinking start to short now… hmmm good luck
Monkey914w OP : reuters.com/sus...